Novel Neoadjuvant Treatment Strategies for Triple-Negative Breast Cancer

Andrew A. Davis, William J. Gradishar

Research output: Contribution to journalArticle

Abstract

Triple-negative breast cancer (TNBC), which accounts for approximately 10% to 15% of breast cancers, remains the most aggressive subtype and is characterized by early disease relapse for a subset of patients. TNBC remains a clinical challenge, given the lack of effective targeted treatments such as endocrine therapy for hormone receptor-positive (HR+) tumors or therapies against HER2.

Original languageEnglish (US)
Pages (from-to)176-182
Number of pages7
JournalOncology (Williston Park, N.Y.)
Volume34
Issue number5
StatePublished - May 13 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Novel Neoadjuvant Treatment Strategies for Triple-Negative Breast Cancer'. Together they form a unique fingerprint.

  • Cite this